A single-arm, phase I-dose escalation trial testing nivolumab combined with NKTR-214, a CD122-preferential IL2 pathway agonist, demonstrated ORR at 59.5% (22/37) and complete response at 18.9% (seven out of 37) for solid tumors patients including NSCLC. The gene discussed is IL2; the disease is non-small cell lung carcinoma.